Insight Inv LLC Trims Stock Position in Labcorp Holdings Inc. $LH

Insight Inv LLC lessened its stake in Labcorp Holdings Inc. (NYSE:LH) by 63.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,410 shares of the medical research company’s stock after selling 2,494 shares during the quarter. Insight Inv LLC’s holdings in Labcorp were worth $395,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of LH. JPL Wealth Management LLC purchased a new position in Labcorp during the third quarter valued at approximately $28,000. Hilton Head Capital Partners LLC acquired a new position in Labcorp in the fourth quarter valued at approximately $27,000. DV Equities LLC purchased a new stake in Labcorp in the 4th quarter worth approximately $29,000. Allied Private Wealth LLC purchased a new stake in Labcorp in the 2nd quarter worth approximately $33,000. Finally, Headlands Technologies LLC grew its stake in shares of Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after purchasing an additional 96 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Transactions at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 4,669 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the transaction, the chief executive officer owned 102,565 shares of the company’s stock, valued at $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the transaction, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. This trade represents a 3.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 9,681 shares of company stock worth $3,027,677 in the last three months. 0.84% of the stock is owned by corporate insiders.

Labcorp Trading Down 1.4%

Shares of NYSE:LH opened at $326.83 on Friday. The business’s 50 day moving average price is $306.88 and its 200-day moving average price is $280.62. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $341.80. The firm has a market capitalization of $26.51 billion, a price-to-earnings ratio of 27.03, a price-to-earnings-growth ratio of 1.85 and a beta of 0.88. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping the consensus estimate of $4.78 by $0.21. The company had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, equities research analysts forecast that Labcorp Holdings Inc. will post 18.32 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio is 23.82%.

Wall Street Analyst Weigh In

LH has been the subject of several recent research reports. Weiss Ratings raised shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Piper Sandler raised their price target on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Morgan Stanley lifted their price objective on shares of Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Robert W. Baird set a $352.00 price objective on shares of Labcorp in a research report on Friday, July 31st. Finally, Mizuho set a $355.00 target price on shares of Labcorp in a research note on Monday, August 10th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp currently has an average rating of “Moderate Buy” and an average price target of $330.00.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.